Medicated Skin Care Products Industry Outlook 2025-2030: Increased OTC Product Demand, Innovations in Formulations, and the Expansion of Online Retail Presents Investment Opportunities
Medicated Skin Care Products Market
Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Medicated Skin Care Products - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Medicated Skin Care Products was valued at US$7.6 Billion in 2024 and is projected to reach US$9.2 Billion by 2030, growing at a CAGR of 3.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Medicated Skin Care Products market.
The growth in the medicated skin care products market is driven by several factors. Firstly, the increasing incidence of skin conditions, driven by factors such as pollution, lifestyle changes, and dietary habits, is propelling the demand for effective treatments. Secondly, advancements in dermatological research and pharmaceutical formulations are leading to the development of more targeted and efficient products. Thirdly, the growing consumer preference for self-medication and OTC treatments is increasing the accessibility and usage of medicated skin care products. Lastly, the expansion of online retail and direct-to-consumer channels is making it easier for consumers to access a wide range of specialized skin care solutions. These factors collectively contribute to the robust growth of the medicated skin care products market.
Key Insights:
Market Growth: Understand the significant growth trajectory of the Cleansers segment, which is expected to reach US$2.9 Billion by 2030 with a CAGR of a 2.9%. The Toners segment is also set to grow at 2.6% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $2.4 Billion in 2024, and China, forecasted to grow at an impressive 4.7% CAGR to reach $1.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
Detailed Market Analysis: Access a thorough analysis of the Global Medicated Skin Care Products Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Medicated Skin Care Products Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
How is the Global Medicated Skin Care Products Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?
Report Features:
Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as Allergan Aesthetics, 3M Company, Bayer AG, Beiersdorf AG, AdvoCare International LP and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 251 companies featured in this Medicated Skin Care Products market report include:
Allergan Aesthetics
3M Company
Bayer AG
Beiersdorf AG
AdvoCare International L.P.
ALBION Co., Ltd.
4life Trademarks, L.L.C.
Absolutely Natural
Amarte USA LLC
Abbe Laboratories, Inc.
Bee-Alive, Inc.
Bausch Health Companies Inc.
Advanced Dermatology and Cosmetic Surgery
Beauty Solutions, Limited
Brevena
The report analyzes the Medicated Skin Care Products market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments: Type (Cleansers, Toners, Scrubs & Masks, Serums, Moisturizers); Distribution Channel (Offline, Online)
Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Key Attributes
Report Attribute
Details
No. of Pages
715
Forecast Period
2024-2030
Estimated Market Value (USD) in 2024
$7.6 Billion
Forecasted Market Value (USD) by 2030
$9.2 Billion
Compound Annual Growth Rate
3.1%
Regions Covered
Global
MARKET OVERVIEW
Tariff Impact on Global Supply Chain Patterns
Competition
Medicated Skin Care Products - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
Medicated Skin Care Products: An Introduction
Growing Prevalence of Skin Diseases and the Unmet Treatment Needs: A Fundamental Growth Driver
Major Skin Diseases Driving the Need for Medicated Skincare Products
Recent Market Activity
MARKET TRENDS & DRIVERS
Medicated Skin Care Domain to Have Real Moment with Innovation Focus
Select Recently Launched Innovative Skin Care Brands
Trending Ingredients for Skin Care Products
Medical Skin Care Products Rank Better than Regular OTC Products
Growing Demand for Products with Visible Results to Push Growth
Rising Incidence of Skin Issues among Children Fuels Demand for Medicated Skincare Products
Increasing Incidence of Skin Cancer Spurs Demand for Dermatological Products
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Multiple Skin Changes During Cancer Treatment Offers Opportunities
Incidence of Different Types of Skin Cancer
Growing Prevalence of Psoriasis Widens the Demand
Rising Incidence of Eczema to Underpin Volume Growth
Increasing Focus on Wellness and Self-Care amidst Mounting Healthcare Costs Drive Healthy Market Growth
Health & Wellness Boosts Demand for Dermocosmetics
Growth in the Global Cosmeceuticals Market Bodes Well for Market Growth
Global Cosmeceutical Market Size (in US$ Billion) for 2019, 2022 and 2025
Cosmeceuticals with Biologically Active Ingredients to Improve Skin Functioning Begin to Find Favor
Rise in Young Population and Skin Conditions Such as Acne Drive Demand for Medicated skin Care Products
Aging Population and their Vulnerability to Age-Related Skin Changes: A Strong Growth Driver
Major Anti-Aging Ingredients of Cosmeceuticals
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Research-Backed Ingredients Hold Preference
Growing Prominence of Personalized Skin Care Prescriptions Benefit Market Penetration
AI Skin Technology Opening New Opportunities for Ultra-Personalized Skincare Shopping
Medicated Skin Care Advancements DriveGrowth
Nano Gold Products Emerge for Combating Aging
Consumer Interest in Natural Ingredients Drive Demand for Natural and Organic Products
Demand for Natural Ingredients for Cosmetic Products Surges
Surging Popularity of Multi-Functional Products Promote Market Expansion
Women: The Dominant Consumer Cluster for Skin Care Products
Physiological Differences Entail Need for Male Specific Products
Gen Z Emerge as an Attractive Target
Focus Grows on Finding Alternatives to Hydroquinone for Pigment Control
Growing Prominence of Non-Invasive Skin Treatments Lends Traction to Market Demand
Growing Online Availability of Medical-Grade Products and Concerns
Increasing Environmental Pollution Drive Demand for Anti-Pollution Skin Care Products
For more information about this report visit https://www.researchandmarkets.com/r/tp65no
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Medicated Skin Care Products Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Factbox-Key elements of EU-U.S. trade deal agreed on Sunday
BRUSSELS (Reuters) -The U.S. and the European Union agreed on a framework trade deal on Sunday, ending months of uncertainty for industry and consumers on both sides of the Atlantic. Here are the main elements of the deal: * Almost all EU goods entering the U.S. will be subject to a 15% baseline tariff, including cars, which now face 27.5%, as well as semiconductors and pharmaceuticals. The 15% tariff is the maximum tariff and is not added to any existing rates. * However, the U.S. is to announce the result of its 232 trade investigations in two weeks and decide separately on tariff rates for chips and pharmaceuticals. Whatever U.S. decisions come later on these sectors will be "on a different sheet of paper", European Commission President Ursula von der Leyen said. * The U.S. and EU will have zero-for-zero tariffs on all aircraft and their components, certain chemicals, certain generic drugs, semiconductor equipment, some agricultural products, natural resources and critical raw materials. More products would be added. The situation for spirits is still to be established. * Tariffs on European steel and aluminium will stay at 50%, but von der Leyen said these would later be cut and replaced by a quota system. * The EU pledged to buy $250 billion of U.S. liquefied natural gas (LNG) a year for three years, totalling $750 billion in total, as it replaces Russian gas. The EU will also buy nuclear fuel from the U.S. * Under the deal, the EU pledged to buy U.S. military equipment and European companies are to invest $600 billion in the U.S. over the course of Trump's second term. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Analysis-Out-gunned Europe accepts least-worst US trade deal
By Mark John LONDON (Reuters) -In the end, Europe found it lacked the leverage to pull Donald Trump's America into a trade pact on its terms and so has signed up to a deal it can just about stomach - albeit one that is clearly skewed in the U.S.'s favour. As such, Sunday's agreement on a blanket 15% tariff after a months-long stand-off is a reality check on the aspirations of the 27-country European Union to become an economic power able to stand up to the likes of the United States or China. The cold shower is all the more bracing given that the EU has long portrayed itself as an export superpower and champion of rules-based commerce for the benefit both of its own soft power and the global economy as a whole. For sure, the new tariff that will now be applied is a lot more digestible than the 30% "reciprocal" tariff which Trump threatened to invoke in a few days. While it should ensure Europe avoids recession, it will likely keep its economy in the doldrums: it sits somewhere between two tariff scenarios the European Central Bank last month forecast would mean 0.5-0.9% economic growth this year compared to just over 1% in a trade tension-free environment. But this is nonetheless a landing point that would have been scarcely imaginable only months ago in the pre-Trump 2.0 era, when the EU along with much of the world could count on U.S. tariffs averaging out at around 1.5%. Even when Britain agreed a baseline tariff of 10% with the United States back in May, EU officials were adamant they could do better and - convinced the bloc had the economic heft to square up to Trump - pushed for a "zero-for-zero" tariff pact. It took a few weeks of fruitless talks with their U.S. counterparts for the Europeans to accept that 10% was the best they could get and a few weeks more to take the same 15% baseline which the United States agreed with Japan last week. "The EU does not have more leverage than the U.S., and the Trump administration is not rushing things," said one senior official in a European capital who was being briefed on last week's negotiations as they closed in around the 15% level. That official and others pointed to the pressure from Europe's export-oriented businesses to clinch a deal and so ease the levels of uncertainty starting to hit businesses from Finland's Nokia to Swedish steelmaker SSAB. "We were dealt a bad hand. This deal is the best possible play under the circumstances," said one EU diplomat. "Recent months have clearly shown how damaging uncertainty in global trade is for European businesses." NOW WHAT? That imbalance - or what the trade negotiators have been calling "asymmetry" - is manifest in the final deal. Not only is it expected that the EU will now call off any retaliation and remain open to U.S. goods on existing terms, but it has also pledged $600 billion of investment in the United States. The time-frame for that remains undefined, as do other details of the accord for now. As talks unfolded, it became clear that the EU came to the conclusion it had more to lose from all-out confrontation. The retaliatory measures it threatened totalled some 93 billion euros - less than half its U.S. goods trade surplus of nearly 200 billion euros. True, a growing number of EU capitals were also ready to envisage wide-ranging anti-coercion measures that would have allowed the bloc to target the services trade in which the United States had a surplus of some $75 billion last year. But even then, there was no clear majority for targeting the U.S. digital services which European citizens enjoy and for which there are scant homegrown alternatives - from Netflix to Uber to Microsoft cloud services. It remains to be seen whether this will encourage European leaders to accelerate the economic reforms and diversification of trading allies to which they have long paid lip service but which have been held back by national divisions. Describing the deal as a painful compromise that was an "existential threat" for many of its members, Germany's BGA wholesale and export association said it was time for Europe to reduce its reliance on its biggest trading partner. "Let's look on the past months as a wake-up call," said BGA President Dirk Jandura. "Europe must now prepare itself strategically for the future - we need new trade deals with the biggest industrial powers of the world." (Additional reporting by Jan Strupczewski in Brussels; Christian Kraemer and Maria Martinez in Berlin; Writing by Mark John; Editing by Nick Zieminski) Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
Stock Investors Expect Rally as Europe Clinches US Trade Deal
Investors expect automakers and luxury goods makers to lead a relief rally in European stocks when the market reopens on Monday, after the US and European Union agreed to a trade deal. The pact, which will see the bloc face 15% tariffs on most of its exports including autos, was announced Sunday by President Donald Trump after a meeting with European Commission President Ursula von der Leyen. The European leader said the rate would be all inclusive, though Trump said it did not include pharmaceuticals and metals.
